Skip to main content
Premium Trial:

Request an Annual Quote

Cengent Inks Drug Discovery Collaboration with Novartis Institutes

NEW YORK, April 12 (GenomeWeb News) - Cengent Therapeutics said today that it has struck a drug discovery deal with the Novartis Institutes for Biomedical Research.


Under the deal, Cengent said it will use its proprietary structure-based lead identification technology to screen for drug candidates against targets identified by the Novartis Institutes.


Financial terms of the deal were not disclosed, but Cengent said the arrangement includes upfront and milestone payments.


The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.